BAYER Australia has announced that the TGA has registered Nubeqa (darolutamide) for metastatic hormone-sensitive prostate cancer, an aggressive form of prostate cancer.
With this extended indication, Nubeqa can now be used in combination with the existing standard of care of docetaxel and androgen-deprivation therapy (ADT), giving clinicians the opportunity to utilise an 'intensive' treatment approach.
Taken as a tablet twice a day, Nubeqa is an androgen receptor inhibitor that works by blocking the activity of male sex hormones (or androgens), such as testosterone, preventing prostate cancer cells from growing and dividing.
The combination of Nubeqa with docetaxel and ADT targets the disease from multiple angles resulting in an intensive approach.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Mar 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Mar 23
